Regulation of prostate cancer progression by galectin-3

American Journal of Pathology

Volumn 174, Issue 4, 2009, Pages 1515-1523

  Wang, Yi ^a   Nangia Makker, Pratima ^a   Tait, Larry ^b   Balan, Vitaly ^a   Hogan, Victor ^a   Pienta, Kenneth J ^c,d   Raz, Avraham ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Michigan ^*  (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; GALECTIN 3; GELATINASE A; GELATINASE B; PROTEIN P21; PROTEIN P27; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RETINOBLASTOMA; TRANSGENIC MOUSE; TUMOR GROWTH; UPREGULATION; ANIMAL; CELL MOTION; DISEASE COURSE; DRUG SCREENING; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; GALECTIN 3; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 65349183478     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080816     Document Type: Article

References (39)

1. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF: Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004, 64:7086-7091
2. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, BismarTA, Kim R, Rubin MA, Pienta KJ: Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004, 64:9209-9216
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26
4. Zhang Z, Li M, Wang H, Agrawal S, Zhang R: Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci USA 2003, 100:11636-11641
5. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE: A urokinase- derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol 2003, 162:619-626
6. Woo HJ, Shaw LM, Messier JM, Mercurio AM: The major non-integrin laminin binding protein of macrophages is identical to carbohydrate binding protein 35 (Mac-2). J Biol Chem 1990, 265:7097-7099
7. Cherayil BJ, Chaitovitz S, Wong C, Pillai S: Molecular cloning of a human macrophage lectin specific for galactose. Proc Natl Acad Sci USA 1990, 87:7324-7328
8. Barondes SH, Cooper DN, Gitt MA, Leffler H: Galectins, structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807-20810
9. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A: The NH2-terminus of galectin-3 governs cellular com- partmentalization and functions in cancer cells. Cancer Res 1999, 59:6239-6245
10. Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, Raz A: Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33:14109-14114
11. Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH: Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998, 49:171-183
12. Lotz MM, Andrews Jr CW, Korzelius CA, Lee EC, Steele Jr GD, Clarke A, Mercurio AM: Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma. Proc Natl Acad Sci USA 1993, 90:3466-3470
13. Strik HM, Deininger MH, Frank B, Schluesener HJ, Meyermann R: Galectin-3: cellular distribution and correlation with WHO-grade in human gliomas. J Neurooncol 2001, 53:13-20
14. Ellerhorst J, Troncoso P, Xu XC, Lee J, Lotan R: Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer. Urol Res 1999, 27:362-367
15. Pacis RA, Pilat MJ, Pienta KJ, Wojno K, Raz A, Hogan V, Cooper CR: Decreased galectin-3 expression in prostate cancer. Prostate 2000, 44:118-123
16. Ahmed H, Banerjee PP, Vasta GR: Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation. Biochem Biophys Res Commun 2007, 358:241-246
17. Merseburger AS, Kramer MW, Hennenlotter J, Simon P, Knapp J, Hartmann JT, Stenzl A, Serth J, Kuczyk MA: Involvement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer. Prostate 2008, 68:72-77
18. Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F: Galectin-3: presurgi- cal marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest 2004, 27:311-317
19. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, Itoh K, Miura S: Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep 2002, 9:1307-1312
20. Gillenwater A, Xu XC, el-Naggar AK, Clayman GL, Lotan R: Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996, 18:422-432
21. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A: Galectin-3 cleavage: a novel surrogate maker for matrix metallo- proteinase activity in growing breast cancers. Cancer Res 2007, 67:11760-11768
22. Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4:425-429
23. Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet
24. C, Sobel ME: Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 1996, 179:43-48
25. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V: Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 1996, 27:1185-1191
26. Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A: Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial- endothelial interactions. Am J Pathol 2004, 165:1931-1941
27. Van den Brule FA, Waltregny D, Liu FT, Castronovo V: Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression. Int J Cancer 2000, 89:361-367
28. Song YK, Billiar TR, Lee YJ: Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 2002, 160: 1069-1075
29. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia- Makker P, Raz A: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galec- tin 3. Gastroenterology 1998, 115:287-296
30. Bresalier RS, Yan PS, Byrd JC, Lotan R, Raz A: Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer
31. 1997, 80:776-787
32. Yang RY, Hsu DK, Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996, 93:6737-6742
33. Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young Jr WF, Vidal S, Kovacs K, Raz A, Lloyd RV: Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003, 63:2251-2255
34. Hsieh TC, Wu JM: Changes in cell growth, cyclin/kinase, endogenous phosphoproteins and nm23 gene expression in human prostatic JCA-1 cells treated with modified citrus pectin. Biochem Mol Biol Int
35. 1995, 37:833-841
36. Nangia-Makker P, Thompson E, Hogan C, Ochieng J, Raz A: Induction of tumorigenicity by galectin-3 in a non-tumorigenic human breast carcinoma cell line. Int J Oncol 1995, 7:1079-1087
37. Honjo Y, Nangia-Makker P, Inohara H, Raz A: Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 2001, 7:661-668
38. Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, Pazerini G, Carmi P: Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990, 46:871-877
39. Ellerhorst JA, Stephens LC, Nguyen T, Xu XC: Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP. Prostate 2002, 50:64-70